Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Contact us
- Phone/fax: +7 495 442 37 85
- Phone: +7 985 908 58 18
- E-mail: info@regdrug.com
- pharegis.com | regdrug.com
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
PSRN: 1157746918933
TAX ID (TIN): 7718278100
D-U-N-S: 362071645
-
- +7 495 442 37 85 9am-6pm GMT+3
-
- + 7 495 442 37 85
-
- + 7 985 908 58 18
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults
- FDA Approves Merck’s Dificid (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
- FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
- FDA Approves Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
- FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease
News and press releases
- Martina Schüssler-Lenz re-elected as chair of Committee for Advanced Therapies, , 24/01/2020
- Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 21-23 January 2020, CVMP, 24/01/2020
- Court of Justice upholds EMA’s approach to transparency, , 22/01/2020
- Ten recommendations to unlock the potential of big data for public health in the EU, , 20/01/2020
Drugs.com - Clinical Trials
- Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy South San Francisco, CA --...
- Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer Cranbury, NJ, Jan. 21, 2020...
- BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysi BEIJING, China,...
- Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection WHITE PLAINS, N.Y., Jan. 15,...